OncLive Staff

Emi-Le generated durable responses and encouraging PFS with manageable safety in patients with aggressive adenoid cystic carcinoma.

Zanubrutinib yielded sustained progression-free survival and a tolerable safety profile in older patients with CLL/SLL treated in the SEQUOIA trial.

Real-world data show liso-cel drives high response rates and durable benefit in relapsed/refractory MCL, including high-risk patients.

Rocbrutinib delivered durable responses and encouraging survival with manageable safety in BTK inhibitor–pretreated relapsed/refractory MCL.

Tuspetinib/venetoclax/azacitidine produced high CR and MRD-negativity rates across molecular subgroups of older or unfit patients newly diagnosed AML.

The first-in-class BTK degrader tacabrutideg produced an ORR of 94.1% at the recommended phase 2 dose in relapsed/refractory CLL/SLL.

Obe-cel delivered durable remissions in relapsed/refractory B-ALL, with the best efficacy and safety seen in patients with low disease burden.

Phase 1 data showed that INCA033989 produced rapid and durable responses as monotherapy and in a combination regimen in CALR-mutated myelofibrosis.

The type II JAK2 inhibitor AJ1-11095 produced SVRs, deep symptom responses, and mutation VAF reductions in type I JAK inhibitor–exposed myelofibrosis.

Luspatercept produced clinically meaningful improvements in RBC transfusion independence in myelofibrosis-associated anemia.

A phase 2 study of dose-adjusted EPOCH plus tafasitamab with or without rituximab met its primary end point of MRD negativity after the first cycle.

Fixed-duration venetoclax/obinutuzumab more than doubled median PFS vs chlorambucil/obinutuzumab in previously untreated CLL.

In the MAXILUS primary analysis, luspatercept initiated at 1.75 mg/kg yielded high RBC transfusion independence rates in lower-risk MDS.

Partial response to bridging therapy before cilta-cel was associated with improved PFS and OS outcomes in relapsed/refractory multiple myeloma.

Ficerafusp alfa plus pembrolizumab generated a 54% ORR and 21.7-month median DOR in first-line HPV-negative recurrent or metastatic HNSCC.

EPCORE FL-1 showed that epcoritamab/lenalidomide/rituximab yielded superior efficacy vs lenalidomide/rituximab across follicular lymphoma populations.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Check out some of the top oncology news and trends of the week.

Varegacestat reduced the risk of disease progression or death by 84% vs placebo in progressing desmoid tumors.

Sintilimab plus adjuvant capecitabine did not improve 2-year PFS outcomes vs capecitabine alone in NPC with suboptimal response to induction chemotherapy.

First-line asandeutertinib improved intracranial iORR and IPFS vs osimertinib in EGFR-mutated NSCLC with brain metastases.

Zanidatamab plus tislelizumab and chemotherapy improved PFS and OS in HER2-positive mGEA regardless of PD-L1 status by TAP score or CPS.

PSMAddition subgroup data show lutetium PSMA-617 triplet yields consistent rPFS, PSA, and mCRPC benefits regardless of disease volume or mHSPC status.

Sacituzumab govitecan plus pembrolizumab improved PFS2 and delayed subsequent therapy vs chemo/pembrolizumab in PD-L1+ mTNBC.

Pemigatinib improved PFS as first-line therapy for FGFR2-rearranged cholangiocarcinoma in the phase 3 FIGHT-302 trial.

Rilvegostomig plus T-DXd yielded high pCR rates in immune-positive HER2-negative breast cancer.

Durvalumab plus BCG maintained overall survival and quality of life in high-risk NMIBC at 5 years.

Circulating tumor DNA analyses from the phase 1/1b StrateGIST-1 trial also support baseline ctDNA detectability as a potentially prognostic marker in this population.

Analyses from the evERA trial showed PFS2 and chemotherapy-free survival gains with giredestrant plus everolimus in ER+ breast cancer subgroups.

CIRCULATE provides the first prospective randomized evidence in support of a ctDNA-guided treatment escalation strategy in pMMR/MSS stage II colon cancer.